SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mesco Pharmaceuticals informs about outcome of board meeting

13 Feb 2019 Evaluate

Pursuant to Regulations 30 and 33 of SEBI (LODR) Regulations, 2015, Mesco Pharmaceuticals has informed about submission of the Standalone unaudited Financial Results and Limited Review Report for the quarter ended on 31st December, 2018, duly considered and approved by the Board of Directors in their Board Meeting held on Wednesday, 13th February, 2019 at New Delhi commenced at 02:00 pm and concluded at 02:50 pm.

The above information is a part of company’s filings submitted to BSE.

Mesco Pharma Share Price

4.54 0.00 (0.00%)
10-Jan-2022 18:01 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1865.95
Dr. Reddys Labs. 1339.35
Cipla 1456.95
Zydus Lifesciences 1108.85
Lupin 2396.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: